Gene therapy trial for early Huntington's disease
Part of Brain & nervous system, Genetic & congenital, Mental health clinical trials.
This trial tests a gene therapy called SPK-10001 for people with early-stage Huntington's disease. It aims to slow the progression of symptoms by targeting the genetic cause of the disease.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must have a genetic test showing 40 or more CAG repeats in the Huntington gene.
- You must have some shrinkage in a specific area of the brain (the striatum) as seen on an MRI or CT scan.
- Your movement symptoms should be noticeable enough to affect daily life, but you should still be able to handle most daily tasks on your own.
- If you take any medications for depression, anxiety, or movement, the doses must have been stable for at least 3 months.
- You cannot have had certain types of brain treatments in the past, like gene therapy, deep brain stimulation, or recent experimental drugs.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a new drug called SKY-0515 in people with Huntington's disease. The goal is to see if it can safely improve symptoms or slow the disease down.
This study tests whether a medication called pridopidine can help slow the progression of Huntington's disease symptoms in adults. Huntington's is a genetic disorder affecting movement, mood, and thinking, and this trial aims to see if pridopidine improves daily functioning and quality of life.
This trial tests whether human neural stem cells are safe and tolerable for people with Huntington's disease. It involves a neurosurgical procedure to inject the cells into the brain, along with MRI scans and other monitoring.
This trial tests a new radioactive tracer called [11C]CHDI-00491009 that may show mutant huntingtin protein in the brain using a PET scan. It aims to find out if the tracer is safe and helps see Huntington's disease changes. If you have early-stage Huntington's or are a healthy volunteer, you may be able to join.
This study uses special brain imaging and memory/thinking tests to find early “markers” that can predict how Huntington’s disease will progress over time. You may qualify as someone with early-stage Huntington’s or as a healthy control, if you meet specific safety and scoring requirements.
This trial tests if a vitamin B3-like supplement, nicotinamide riboside, can help people with early to mid-stage Huntington's disease. You will be randomly assigned to take the supplement or a placebo to see if it slows the disease.
Hear when a new Huntington Disease trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.